

GLIOTEX

The glioblastoma drug evaluation service

Our expertise

We speed up the evaluation of your innovative therapies in relevant preclinical models of glioblastoma enabling rapid evaluation in clinical trials.

700+ Tumour samples


49 Patients-derived cell lines

20 Orthotopic patient-derived xenograft animal models

Target characterization on GBM tissue

Your therapeutic strategy is evaluated on GBM human tissue to ensure relevant pre-clinical studies.

Assays: Evaluation of a limited number of targets (IHC, sequencing, qPCR) / Genome-wide evaluation (NGS, Micro-arrays)




Human tumor cells, engrafted in mouse brain, are stained in red

In vitro patient-derived cell lines assays

We offer in vitro efficacy studies of existing or novel anti-cancer therapies in 49 patient-derived cell lines phenocopying molecular alterations characterized in parental tumour they derived from.

Assays: Proliferation / Apoptosis



Patient-derived cell lines grow as spheres in suspension in serum free media

Orthotopic PDCLXs efficacy studies

We offer in vivo efficacy studies of existing or novel anti-cancer therapies in xenograft tumour models using 20 patient-derived cell lines.

Assays: Tumour monitoring (Bioluminescence and/or MRI) / Animal survival analysis / Histology



Bioluminescence signal to monitor tumor growth